We read with great interest the recent article by Tsai et al,1 which compared characteristics between primary neuromyelitis ...
Climb Bio, Inc. (Nasdaq: CLYM), a clinical stage biotechnology company developing therapeutics for patients with ...
A phase 1 trial of a human thymus-expressed apoptosis factor in patients with advanced solid tumors: Interim report. This is an ASCO Meeting Abstract from the 2015 ASCO Annual Meeting I. This abstract ...
Robust B-cell depletion observed with budoprutug subcutaneous formulation in healthy volunteers, supporting continued ...
B-cell depletion is effective in MS and NMOSD, with anti-CD20 and anti-CD19 mAbs showing distinct mechanisms impacting safety and tolerability. Glycoengineering enhances ADCC activity, mitigating ...
SAVANNAH, Ga. -- Inebilizumab (Uplizna) had clinically meaningful efficacy and a favorable safety profile among people with generalized myasthenia gravis (gMG), topline data from the MINT trial showed ...
Budoprutug CD19 R&D Spotlight held May 5, 2026. The Company held a webcast to review the development strategy and program updates for budoprutug, the potential opportunity presented by targeting CD19, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results